3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
6
Neoplasms by Site
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer Not Immediately Operated
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Interventions
abemaciclib
3
Fulvestrant
3
Anastrozole
3
ribociclib
2
palbociclib
2
exemestane
2
Tamoxifen
2
Letrozole
2
trastuzumab deruxtecan
1
taxane
1
pertuzumab
1
elacestrant
1
dalpiciclib
1
Trastuzumab
1
STX-478
1
RAD1901
1
Metformin
1
Leflunomide
1
Imlunestrant
1
Gonadotropin-Releasing Hormone
1
Genotype
1
Body Height
1
Blood Pressure
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Diseases
×
ribociclib
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled